Sarepta Therapeutics Inc  

(Public, NASDAQ:SRPT)   Watch this stock  
Find more results for SRPT
-1.25 (-3.83%)
After Hours: 31.13 -0.28 (-0.89%)
Jan 23, 6:00PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.22 - 32.63
52 week 8.00 - 63.73
Open 32.55
Vol / Avg. 0.00/2.70M
Mkt cap 1.64B
P/E     -
Div/yield     -
EPS -5.27
Shares 54.59M
Beta 1.90
Inst. own 81%
Feb 23, 2017
Q4 2016 Sarepta Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 10, 2017
Sarepta Therapeutics Inc at JPMorgan Healthcare Conference (Q&A Session)
Jan 10, 2017
Sarepta Therapeutics Inc at JPMorgan Healthcare Conference
Nov 7, 2016
Sarepta Therapeutics Inc at Credit Suisse Healthcare Conference
Oct 27, 2016
Q3 2016 Sarepta Therapeutics Inc Earnings Release
Oct 27, 2016
Q3 2016 Sarepta Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin - -17560.26%
Operating margin - -17572.54%
EBITD margin - -17153.79%
Return on average assets -65.84% -77.36%
Return on average equity -85.87% -100.47%
Employees 270 -
CDP Score - -


215 1st St Ste 415
CAMBRIDGE, MA 02142-1213
United States - Map
+1-617-2744000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Officers and directors

Edward M. Kaye M.D. President, Chief Executive Officer, Chief Medical Officer, Director
Age: 67
Bio & Compensation  - Reuters
Sandesh Mahatme Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
David Tyronne Howton Senior Vice President, General Counsel, Corporate Secretary
Age: 44
Bio & Compensation  - Reuters
Shamim Ruff Senior Vice President - Regulatory Affairs and Quality
Bio & Compensation  - Reuters
Joan Wood Vice President - Human Resources
Bio & Compensation  - Reuters
Jayant Aphale Ph.D. Vice President - Technical Operations
Age: 55
Bio & Compensation  - Reuters
Alexander Cumbo Vice President, Head of Commercial
Bio & Compensation  - Reuters
Richard J. Barry Independent Director
Age: 57
Bio & Compensation  - Reuters
M. Kathleen Behrens Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Jean-Paul Kress M.D. Independent Director
Age: 50
Bio & Compensation  - Reuters